Register to Win a Pair of Tickets to see SO TRUE LIVE TOUR WITH CALEB HEARON Register to Win a Pair of Tickets to see SO TRUE LIVE TOUR WITH CALEB HEARON Music and the Mirror (& Mobility Aids): ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association between aromatase inhibitor treatment (AIT) and ischaemic cardiotoxicity ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China ...

[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

Aromatase inhibitors (AIs) are a class of drugs that block the aromatase enzyme, which is responsible for converting androgens (male hormones) into estrogens (female hormones). These medications ...

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression. A national study ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

Prescribing drugs "off-label" means that a healthcare provider has prescribed a medication ... One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone ...